Unibest

Pharmaceutical intermediates

Nemorexant Intermediates

8 pharmaceutical intermediates for Nemorexant. Indication: Sleep Initiation and Maintenance Disorders; Insomnia.

提交项目All intermediates

About Nemorexant

Originator
Actelion Pharmaceuticals Ltd
Indication
Sleep Initiation and Maintenance Disorders; Insomnia
Approved Date
04/07/2022
NCE Patent
04/07/2027
DS/DP
06/12/2033

Available intermediates

8 intermediates currently listed for Nemorexant. Request specifications, documentation or a quotation for any item below.

Nemorexant intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-Methyl-L-proline Methyl ester hydrochloride220060-08-2//
2-Iodo-5-methoxybenzoic acid54413-93-3//
5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid1293284-55-5//
1H-Benzimidazole, 6-chloro-7-methyl-2-[(2S)-2-methyl-2-pyrrolidinyl]-, hydrochloride (1:1)1788104-76-6//
(S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid103336-06-7//
(S)-2-Methylpyrrolidine-2-carboxylic acid hydrochloride1508261-86-6//
6-Chloro-2,3-diaminotoluene673487-36-0//
4-Chloro-3-Methylbenzene-1,2-diaMine hydrochloride1087743-89-2//

Other programs under N

Nafamostat mesylateNebivolol HydrochlorideNeratinib/ PyrotinibNilotinibNintedanib EsylateNiraparib

Building toward Nemorexant?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →